Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

101. Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report

lung cancers are epithelial tumours that develop from squamous or glandular epithelium (adenocarcinoma) [9]. Lung carcinoma is also referred to as bronchial carcinoma since this malignant tumour arises from the bronchial epithelium [10, 11]. It is classified into the following main histological types [12]: ? Small cell lung cancer (SCLC; approx. 15%) ? Non-small cell lung cancer (NSCLC; approx. 85%): ? squamous cell carcinoma: spindle cell variant (40%) Extract of rapid report V18-03 Version 1.0 (...) malignant tumours in the lung Malignant lymphomas and sarcomas are cancerous tumours that can arise as primary thoracic tumours or as lung metastases [14]. Metastases to the lung often also develop in connection with carcinomas of the colon, rectum, kidney, breast, prostate, and oropharynx [15]. Diffuse malignant pleural mesothelioma originates in the mesothelial or submesothelial cells of the pleura, peritoneum, or pericardium. More than 80% of mesotheliomas originate in the pleura. Mesothelioma

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

102. Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Gibbert ? Thomas Kaiser ? Petra Kohlepp ? Ulrike Lampert ? Katrin Nink Keywords: osimertinib, carcinoma – non-small-cell lung, benefit assessment, NCT02296125 Extract of dossier assessment A18-45 Version 1.0 Osimertinib (non-small cell lung cancer) 11 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SBG) V, the Federal Joint Committee (G-BA) commissioned the Institute (...) Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Osimertinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

103. Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

-small cell lung cancer (NSCLC) whose tumours express programmed cell death ligand-1 (PD-L1) on = 1% of tumour cells and whose disease did not progress following platinum-based chemoradiotherapy. Table 2 presents the research question of the benefit assessment and the ACT specified by the G-BA. Table 2 2 : Research question of the benefit assessment of durvalumab Indication ACT a Adults with locally advanced, inoperable NSCLC whose tumours express PD-L1 on = 1% of tumour cells and whose disease has (...) Durvalumab (locally advanced, unresectable NSCLC) 10 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - Included were adult patients with locally advanced, inoperable NSCLC (stage III according to the International Association for the Study of Lung Cancer [IASLC] Version 7) with no disease progression following definitive, combined, platinum-based chemoradiotherapy. In the study, 713 patients were randomized, 476 to the intervention arm and 237 to the comparator arm. In both

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

104. Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

cancer (MK-3475- 021/KEYNOTE-021): study results [online]. In: ClinicalTrials.gov. 30.01.2019 [Accessed: 16.05.2019]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02039674. Merck Sharp Dohme. A phase 1/2 study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lung carcinoma: study P021V03MK3475; clinical study report [unpublished]. 2018. Merck Sharp Dohme. Pembrolizumab KEYNOTE 021G trial platinum therapy (...) Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (nicht plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

105. Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

: hazard ratio; n: number of patients with at least one event; N: number of analysed patients; NA: not achieved; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-Lung Cancer 13; RCT: randomized controlled trial; SAE: serious adverse event; TPS: Tumour Proportion Score; VAS: visual analogue scale; vs.: versus Based on the available data, at most indications, e.g. of an added benefit, can be derived for the outcomes “symptoms” (measured with the EORTC QLQ-C30 (...) Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

106. Delivering best practice lung cancer care - a guide for health professionals

, investigate and refer patients with symptoms that may be lung cancer according to best practice evidence. 32 ` ` Services should have clearly documented pathways and facilitate timely and streamlined referral of patients into the specialist lung cancer team for diagnosis, staging and treatment in line with the national Optimal Care Pathway. 30,31 ` ` Clearly defined evidence-based treatment pathways for patients with lung cancer should be developed according to disease stage. ` ` All patients (...) . 46. Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. European Journal of Cardio-Thoracic Surgery. 2010;38(1):1-5. 47. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews. 2016;42:56-72. 48. Boxer MM, Vinod SK, Shafiq J

2018 Cancer Australia

107. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

2018 FDA - Drug Approval Package

108. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

2018 European Medicines Agency - EPARs

109. Patient Navigation Models for Lung Cancer

Patient Navigation Models for Lung Cancer Rapid Evidence Product Patient Navigation Models for Lung Cancer eRapid Evidence Product Patient Navigation Models for Lung Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for Lung Cancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19

2018 Effective Health Care Program (AHRQ)

110. 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? Full Text available with Trip Pro

30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? Systemic treatment is the standard treatment for unresectable stage III and IV lung cancer. Nevertheless, a 5-10% death rate has been described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We analysed the 30-day mortality after start of systemic therapy. Data were retrieved from the Netherlands National Cancer Registry (...) . From 2010 to 2015, 26 277 patients were included. 56% were men. The median age was 65 years and 31% of patients were aged ≥70 years. 27% involved small cell lung cancer and 73% nonsmall cell lung cancer. Overall mortality within 30 days after the start of systemic treatment was 6.2%. Multivariable analysis established the prognostic influence of age, histology, number of metastatic sites and type of systemic treatment. Chemotherapy was administered in 77 hospitals, treating each 15-161 lung cancer

2018 ERJ open research

111. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

? Judith Gibbert ? Thomas Kaiser ? Ulrike Lampert ? Katrin Nink Keywords: atezolizumab, carcinoma – non-small-cell lung, benefit assessment, NCT02008227 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of figures v List of abbreviations vi 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question (...) (Institute for Quality and Efficiency in Health Care) NSCLC non-small cell lung cancer PD-L1 programmed cell death ligand 1 PT Preferred Term QLQ-C30 Quality of Life Questionnaire-Core 30 QLQ-LC13 Quality of Life Questionnaire-Lung Cancer 13 RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics TC tumour cells Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

112. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study (Abstract)

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung (...) 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly

2018 EvidenceUpdates

113. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (Abstract)

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned (...) , 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.

2018 EvidenceUpdates

114. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial (Abstract)

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous (...) tinzaparin 100 IU·kg-1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean±sd age was 61.6±8.9 years, 190 (34.6%) patients had stage II-III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival

2018 EvidenceUpdates

115. Lung Cancer Screening

of cancer death in both men and women [1]. Smoking is the single greatest risk factor for the development of lung cancer; additional risk factors include radon exposure, occupational exposure to asbestos or other carcinogens, personal history of cancer, family history of lung cancer, history of chronic obstructive pulmonary disease (COPD), and history of pulmonary fibrosis. Both the treatment and prognosis for lung cancer depend upon the stage of the disease, with smaller and less- extensive tumors (...) tending to have longer survivals. The goal of lung cancer screening is to detect early-stage disease before it becomes clinically evident and when appropriate treatment can lead to improved survival. Special Imaging Considerations Unlike conventional chest CT scans performed for other reasons, those done for the purpose of lung cancer screening should be performed using a technique to keep the radiation dose to the patient as low as reasonably achievable. In general, acceptable low-dose lung cancer

2018 American College of Radiology

116. Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC)

is Imfinzi and what is it used for? Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1. Imfinzi contains the active substance durvalumab. How is Imfinzi used? Imfinzi (...) cells and thereby slow down the progression of the disease. Imfinzi (durvalumab) EMA/521637/2018 Page 2/2 What benefits of Imfinzi have been shown in studies? Imfinzi has been shown to be more effective than placebo (a dummy treatment) at prolonging the time patients with advanced non-small cell lung cancer lived without their disease getting worse. In one main study of 713 patients, patients given Imfinzi lived on average for around 17 months without their disease getting worse, compared with 6

2018 European Medicines Agency - EPARs

117. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing [5]. The World Health Organization (WHO) estimates that lung cancer is the cause of 1.59 million deaths globally per year, with 71% of them caused by smoking (...) . For permissions, please email: journals.permissions@oup.com. Annals of Oncology 29 (Supplement 4): iv192–iv237, 2018 doi:10.1093/annonc/mdy275 Published online 3 October 2018; updated 26 January 2019 Downloaded from https://academic.oup.com/annonc/article-abstract/29/Supplement_4/iv192/5115264 by guest on 26 March 2019have resulted in ‘non-smoking-associated lung cancer’ being con- sidered a distinct disease entity, where speci?c molecular and genetic tumour characteristics have been identi?ed [14]. Use

2018 European Society for Medical Oncology

118. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2018 Health Canada - Drug and Health Product Register

119. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

, distance evaluation). 9. We suggest that low-dose CT screening programs develop strategies to minimize overtreatment of potentially indolent lung cancers. (Ungraded Consensus-Based Statement) Remark: It is important to educate patients about the potential to detect an indolent lung cancer to help mitigate the psychologicaldistress that could resultfrom living with an indolent untreated lung cancer. Remark: For malignant nodules, pure ground glass is the nodule morphology most likely to represent (...) of screen-detected ?ndings, or tolerate treatment of an early-stage screen-detected lung cancer, or that substantially limit their life expectancy, we recommend that low-dose CT screening should not be performed. (Strong recommendation, low-quality evidence) Remark: At very severe stages ofa comorbid condition it can be clear that low-dose CT screening is not indicated (eg, advanced liver disease, COPD with hypoventilation and hypoxia, NYHA class IV heart failure) because competing mortality limits

2018 American College of Chest Physicians

120. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Full Text available with Trip Pro

Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer.To project reductions in tobacco use and lung cancer mortality from 2015 to 2065 due to existing tobacco control efforts.Comparative modeling approach using 4 simulation models of the natural history of lung cancer (...) that explicitly relate temporal smoking patterns to lung cancer rates.U.S. population, 1964 to 2065.Adults aged 30 to 84 years.Models were developed using U.S. data on smoking (1964 to 2015) and lung cancer mortality (1969 to 2010). Each model projected lung cancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios.Under the assumption of continued decreases

2018 Annals of Internal Medicine